UoH’s ASPIRE-BioNEST & Indian Immunologicals Partner to Fast-Track One Health Biotech Innovation

Startups incubated at ASPIRE-BioNEST will gain access to IIL’s technical mentorship, domain expertise, and advanced R&D infrastructure, including facilities relevant to viral and bacterial vaccine development.

The Life Sciences incubation centre at the University of Hyderabad, ASPIRE-BioNEST, has entered into a strategic partnership with Indian Immunologicals to accelerate biotech innovation aligned with the One Health framework, enabling startups to move faster from research to real-world deployment.

The collaboration builds on India’s growing emphasis on integrating human, animal, and environmental health systems through the One Health approach. With rising zoonotic risks and public health challenges, partnerships between academia and industry have become critical to accelerate innovation, particularly in vaccines, diagnostics, and medical technologies.

Indian Immunologicals, a subsidiary of the National Dairy Development Board, has established capabilities in vaccine development and manufacturing, making it a key industry partner for translational biotech initiatives.

Under this agreement, startups incubated at ASPIRE-BioNEST will gain access to IIL’s technical mentorship, domain expertise, and advanced R&D infrastructure. This includes facilities for process development, analytical testing, and capabilities relevant to viral and bacterial vaccine development.

The partnership will also explore opportunities to utilize IIL’s contract development and manufacturing (CDMO) services, helping startups navigate scale-up and manufacturing readiness more efficiently.

The MoU further enables joint efforts in co-development, validation, and technology transfer, while opening pathways for market access. By bridging gaps between innovation, regulation, and commercialization, the collaboration aims to improve the success rate of early-stage biotech ventures transitioning into deployable products.

As part of the engagement, Dr Anand Kumar interacted with startups at ASPIRE-BioNEST, offering practical insights into product development, regulatory pathways, and scaling strategies.

He stated that Indian Immunologicals will actively support startups at ASPIRE-BioNEST by extending its full spectrum of expertise across the product development lifecycle, from early-stage research and validation to scale-up, regulatory pathways, and commercialization.

He emphasized that IIL will work closely with startups to translate promising innovations into viable, market-ready products by leveraging its experience, infrastructure, and industry insights, thereby accelerating commercialization and enabling globally competitive solutions.

Dr Anil Kondreddy, CEO of ASPIRE-BioNEST, highlighted that such partnerships are essential for enabling startups to transition from proof-of-concept to scalable, market-ready products by providing access to industry expertise, infrastructure, and commercialization pathways.

Both organizations also plan to co-host initiatives such as hackathons, pre-incubation programs, and knowledge-sharing events to strengthen the broader startup ecosystem.

Stay tuned for more such updates on Digital Health News